Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDRH’s Mansfield Addresses Upcoming Drug/Dx Co-Development Guidance

This article was originally published in The Gray Sheet

Executive Summary

Either an IND or an IDE will be sufficient for companion diagnostic studies, a CDRH diagnostics official clarified last week. That is among the issues that will be addressed in an upcoming co-development draft guidance.

You may also be interested in...



FDA Companion, Co-Development Dx Guidances On Track, Official Says

FDA aims to issue both a final companion diagnostics guidance document and a separate draft guidance on the co-development of drugs and tests in the coming months.

Companion Dx Partnerships, M&A Deals Help Spur IVD Market Growth – PWC Report

A report from PricewaterhouseCoopers suggests the in vitro diagnostics market will see accelerated growth next year due in part to a surge in companion diagnostics partnerships and M&A deals.

Companion Dx Partnerships, M&A Deals Help Spur IVD Market Growth – PWC Report

A report from PricewaterhouseCoopers suggests the in vitro diagnostics market will see accelerated growth next year due in part to a surge in companion diagnostics partnerships and M&A deals.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT030716

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel